review Open AccessTop 1% cited

Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 Studies

PLoS Medicine · 2010 · Vol. 7(5) · pp. e1000279–e1000279

Fiona M. Blows(University of Cambridge)Kristy Driver(University of Cambridge)Marjanka K. Schmidt(Oncode Institute)Annegien Broeks(The Netherlands Cancer Institute)Flora E. van Leeuwen(The Netherlands Cancer Institute)Jelle Wesseling(Oncode Institute)Maggie C.U. Cheang(University of British Columbia)Karen A. Gelmon(University of British Columbia)Torsten O. Nielsen(University of British Columbia)Carl Blomqvist(Helsinki University Hospital)Päivi Heikkilä(Helsinki University Hospital)Tuomas Heikkinen(Helsinki University Hospital)Heli Nevanlinna(Helsinki University Hospital)Lars A. Akslen(Haukeland University Hospital)Louis R. Bégin(McGill University)William D. Foulkes(McGill University)Fergus J. Couch(Mayo Clinic)Xianshu Wang(Mayo Clinic)Vicky Cafourek(Mayo Clinic in Florida)Janet E. Olson(Mayo Clinic in Florida)Laura Baglietto(Cancer Council Victoria)Graham G. Giles(Cancer Council Victoria)Gianluca Severi(Cancer Council Victoria)Catriona McLean(The Alfred Hospital)Melissa C. Southey(The University of Melbourne)Emad A. Rakha(University of Nottingham)Andrew R. Green(University of Nottingham)Ian O. Ellis(Nottingham City Hospital)Mark E. Sherman(Division of Cancer Epidemiology and Genetics)Jolanta Lissowska(The Maria Sklodowska-Curie National Research Institute of Oncology)William F. Anderson(Division of Cancer Epidemiology and Genetics)Angela Cox(University of Sheffield)Simon S. Cross(University of Sheffield)Malcolm Reed(University of Sheffield)Elena Provenzano(University of Cambridge)Sarah‐Jane Dawson(University of Cambridge)Alison M. Dunning(University of Cambridge)Manjeet K. Humphreys(University of Cambridge)Douglas F. Easton(University of Cambridge)Montserrat García‐Closas(National Cancer Institute)Carlos Caldas(University of Cambridge)Paul D.P. Pharoah✉(University of Cambridge)David G. Huntsman(University of British Columbia)

View via DOI Full-text PDF

Abstract

The six subtypes of breast cancer defined by expression of five markers show distinct behaviours with important differences in short term and long term prognosis. Application of these markers in the clinical setting could have the potential to improve the targeting of adjuvant chemotherapy to those most likely to benefit. The different patterns of mortality over time also suggest important biological differences between the subtypes that may result in differences in response to specific therapies, and that stratification of breast cancers by clinically relevant subtypes in clinical trials is urgently required.

Breast Cancer Treatment Studies HER2/EGFR in Cancer Research Breast Lesions and CarcinomasBreast cancerImmunohistochemistrySubtypingCytokeratinOncologyInternal medicineHormone receptorProgesterone receptorCancerBasal (medicine)

MeSH terms

AdultAgedAged, 80 and overBreast NeoplasmsFemaleHormonesHumansImmunohistochemistryKeratinsMiddle AgedPrognosisReceptors, Cell SurfaceBiomarkers, TumorProportional Hazards ModelsYoung Adult